Browsing Tag
peptide drug conjugate
4 posts
Avacta (AIM: AVCT) opens AVA6103 Phase 1: Can sustained-release engineering salvage exatecan’s clinical legacy?
Avacta Therapeutics opens Phase 1 enrollment for AVA6103 exatecan PDC at two US oncology centers. Early data expected H2 2026. Read what it means for AVCT investors.
Avacta Group PLC (AIM: AVCT) shares rise on dual payload breakthrough: Is a clinical re-rating next?
Avacta shares rise after unveiling dual payload cancer therapy at AACR-NCI-EORTC. Can the stock sustain momentum as it approaches clinical milestones?
Theratechnologies to unveil promising long-term efficacy for sudocetaxel zendusortide in solid tumors at ASCO 2024
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical leader focused on innovative therapy developments, has revealed Phase 1…
Avacta Group advances Phase 1 trial of oncology drug candidate AVA6000
Avacta Group plc (AIM: AVCT), a prominent life sciences company, has achieved a significant milestone in its Phase…